Clinical trials: Bladder Cancer Treatment
Bladder Cancer
Optimized Treatment Strategy for HighGrade1 (HGT1) Bladder Cancer Based on Substaging: a Prospective Observational Cohort Study
Non-muscle invasive bladder cancer of High Grade stage T1 (HGT1), has up to 20% risk of progression to invasive disease. Because the depth of substaging seems to identify two separate groups with different progression risk…
- Trial name
- NCT02113501
- Where
- Spain
- Volunteers
- 200 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Bladder Cancer, Urethral Cancer
Combination Chemotherapy in Treating Patients With Bladder Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003701
- Testing
- carboplatin, cisplatin, doxorubicin hydrochloride
- Where
- 13 sites in United States
- Volunteers
- 490 people
- Sponsor
- Eastern Cooperative Oncology Group
Cancer
External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Indinavir and ritonavir may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00637637
- Testing
- indinavir sulfate, ritonavir, radiation therapy
- Where
- 3 sites in Switzerland
- Volunteers
- 60 people
- Sponsor
- Oncology Institute of Southern Switzerland
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Combination Chemotherapy Following Surgery in Treating Patients With Urinary Tract Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00028860
- Testing
- filgrastim, carboplatin, gemcitabine hydrochloride
- Where
- United States
- Sponsor
- Tulane University Health Sciences Center
Bladder Neoplasms, Carcinoma, Transitional Cell
A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder
Patients with superficial transitional cell carcinoma of the bladder will be treated with intravesical suramin in a phase I dose escalating study. The toxicity of suramin administered in this fashion will be evaluated.
- Trial name
- NCT00001381
- Testing
- suramin
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Bladder Cancer
Transurethral Resection and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combination chemotherapy combined with transurethral resection may kill more tumor cells.
- Trial name
- NCT00003640
- Testing
- filgrastim, cisplatin, doxorubicin hydrochloride
- Where
- Italy
- Volunteers
- 73 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Neoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radical Cystectomy for Locally Advanced Carcinoma (Cancer) of the Urothelium
RATIONALE: Drugs used in chemotherapy, such as ifosfamide, doxorubicin, gemcitabine, and cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00080795
- Testing
- filgrastim, cisplatin, doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- M.D. Anderson Cancer Center
Cancer, Childhood Cancer
Bladder and Bone Effects of Pelvic Radiation Therapy in Childhood Cancer Survivors
The aim of this study is to measure and evaluate the effects of pelvic external beam radiation therapy (EBRT) on lower urinary tract (LUT) function and bone mineralization.
- Trial name
- NCT05818462
- Testing
- Uroflow testing, Bladder Scan, Dysfunctional Voiding Scoring System Survey
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Colorado, Denver
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Fluorouracil in Treating Patients With Recurrent or Metastatic Bladder Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of fluorouracil given as a continuous infusion in treating…
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00003175
- Testing
- fluorouracil
- Where
- 62 sites in Brazil, Canada and 6 more
- Volunteers
- 45 people
- Sponsor
- Medical Research Council
Bladder Cancer
Loop Resectoscope in Treating Patients With Bladder Cancer or Benign Prostatic Hyperplasia Who Are Undergoing Transurethral Resection
RATIONALE: Transurethral resection is a less invasive type of surgery for bladder cancer or benign prostatic hyperplasia. Transurethral resection using a loop resectoscope may have fewer side effects and improve recovery.
- Trial name
- NCT00303654
- Testing
- biopsy, therapeutic conventional surgery
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Roei Medical Technologies Ltd.
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
S0400, FR901228 in Treating Patients With Advanced Cancer of the Urothelium
RATIONALE: Drugs used in chemotherapy, such as FR901228 (depsipeptide), work in different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00087295
- Testing
- Depsipeptide
- Volunteers
- 6 people
- Sponsor
- SWOG Cancer Research Network
Stage 0 Bladder Urothelial Carcinoma, Stage 0is Bladder Urothelial Carcinoma
S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer
This randomized phase III trial studies Tokyo-172 strain bacillus Calmette-Guerin (BCG) solution with or without a vaccination using Tokyo-172 strain BCG to see how well it works compared with TICE BCG solution in treating…
- Conditions
- Stage 0 Bladder Urothelial Carcinoma, Stage 0is Bladder Urothelial Carcinoma, Stage I Bladder Urothelial Carcinoma
- Trial name
- NCT03091660
- Testing
- BCG Solution, BCG Tokyo-172 Strain Solution, BCG Tokyo-172 Strain Vaccine
- Where
- 174 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- SWOG Cancer Research Network
Cancer
Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor
RATIONALE: When irradiated lymphocytes from a donor are infused into the patient they may help the patient's immune system kill cancer cells.
- Trial name
- NCT00161187
- Testing
- therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Transitional Carcinoma of Urinary Bladder
Phase II Trial of Concurrent Administration of Intravesical BCG & Interferon in the Treatment and Prevention of Recurrence of Superficial Transitional Carcinoma of the Urinary Bladder
Phase II Trial of concurrent administration of intravesical BCG \& Interferon in the treatment and prevention of recurrence of superficial transitional carcinoma of the urinary bladder.
- Trial name
- NCT00539773
- Testing
- BCG, Interferon
- Volunteers
- 10 people
- Sponsor
- King Faisal Specialist Hospital & Research Center
Bladder Cancer, Kidney Cancer
Ex VIvo DEtermiNed Cancer Therapy
EVIDENT's aim is to test if ex vivo drug screening can predict whether patients with solid cancers will respond, or not respond, to standard care treatments.
- Conditions
- Bladder Cancer, Kidney Cancer, Melanoma, Sarcoma
- Trial name
- EVIDENT (NCT05231655)
- Testing
- Functional drug screen
- Where
- United Kingdom
- Volunteers
- 600 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Cancer, Neoadjuvant Therapy
Development and Validation of a Multimodal Fusion Artificial Intelligence Model for Predicting the Efficacy of Neoadjuvant Treatment of Bladder Cancer
This study is a multi-center observational study without interventions, including the construction of an AI predictive model, with retrospective and prospective testing.
- Trial name
- NCT06909643
- Testing
- Artificial intelligence (AI)-based predictive model
- Where
- China
- Volunteers
- 469 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Bladder Cancer
Radiation Therapy and Chemotherapy Following Surgery in Treating Patients With Stage II or Stage III Bladder Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00003642
- Testing
- cisplatin, fluorouracil, radiation therapy
- Where
- 3 sites in France, Netherlands
- Volunteers
- 43 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Bladder Cancer
The Application Value of Artificial Intelligence in MRI Precision Diagnosis and Treatment of Bladder Cancer
This study was a prospective, multicenter observational clinical study, A total of 150 patients with bladder malignant tumor who was admitted to the urology department of each center for treatment and underwent electric resection…
- Trial name
- NCT05096533
- Where
- China
- Volunteers
- 150 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Laser-Induced Scar, Breast Cancer
Laser Treatment of Genito-urinary Syndrome in Women
Women with genitourinary syndrome of menopause, overactive bladder, with breast or endometrial cancer are randomized to either laser treatment og sham treatment for 3 months.
- Conditions
- Laser-Induced Scar, Breast Cancer, Endometrial Cancer, Menopause
- Trial name
- NCT03238053
- Testing
- Vaginal laser treatment, laser system
- Where
- Denmark
- Sponsor
- Herning Hospital
Non-muscle Invasive Bladder Cancer
Clinical and Functional Consequences of Photodynamic Diagnosis (PDD) and Intravesical Instillation Therapy
The aim is to evaluate and compare treatment strategies for non-muscle invasive bladder cancer. Furthermore, the impact of intravesical instillations on bladder function will be examined by urodynamic examination both prior to…
- Trial name
- URODYN (NCT04943094)
- Testing
- Urodynamic examination
- Where
- Denmark
- Volunteers
- 50 people
- Sponsor
- Aarhus University Hospital